As FRGs, GOT1 has only been proved to be a biomarker of ccRCC patients in clinical prediction models, which also needs further basic experiments to explore (Chang et al., 2021; Hong et al., 2021). Here, GOT1 is linked to nonpapillary renal cell carcinoma.